UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITY BIOTECHNOLOGY, INC.

(Exact name of Registrant as Specified in Its Charter)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

This filing amends Item 5.02 of the Current Report on Form 8-K filed by Unity Biotechnology, Inc. (the “Company”) with the Securities and Exchange Commission on April 11, 2023. As reported on April 11, 2023, the Company and Jamie Dananberg agreed that Dr. Dananberg would be leaving his employment with the Company on April 30, 2023. In connection with his departure as an employee on April 30, 2023, the Company and Dr. Dananberg entered into a Separation Agreement, dated April 27, 2023, pursuant to which Dr. Dananberg will receive, in addition to any accrued obligations, (i) a severance payment equal to nine months of his base salary in a lump sum payment and (ii) continued health care coverage for himself and his covered dependents under the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, until the earlier of the nine month anniversary of his separation date or the date he becomes eligible for healthcare coverage from another employer. Dr. Dananberg has agreed to provide a full release of claims in favor of the Company. In addition, the Company and Dr. Dananberg entered into a Consulting Agreement, dated April 27, 2023, pursuant to which Dr. Dananberg will continue to provide advice and assistance with the Company’s clinical development programs and related matters in exchange for continued vesting of his equity awards and compensation at the rate of $500 per hour for services rendered above and beyond a monthly eight-hour threshold.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.